Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in ...

Drugmaker Novo Nordisk is once again Europe's largest company by market capitalisation, rising above German software firm SAP ...

Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's blockbuster weight-loss drugs Ozempic and Wegovy, upholding the U.S. Food and ...

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk amid investor concerns that the Danish ...

CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...

A Swiss-led team has developed an AI-driven legged robot that can play badminton against human opponents, demonstrating precise coordination and accuracy. Alice Rizzo reports.

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...